Mostafa Akbarzadeh-Khiavi (Mostafa Akbarzadeh Khiavi)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 8

Top Venues

BioImpacts : BI

Expert opinion on biological therapy

Tabriz University of Medical Sciences

Tabriz University of Medical Sciences (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tabriz University of Medical Sciences Jun 10 2020

Iran

Assistant Professor

Education History

Tabriz University of Medical Sciences Aug 01 2012 - Jun 25 2019

Iran

PHD :: LGDRC

Publications

Mostafa Akbarzadeh-Khiavi, Azam Safary, Yadollah Omidi
Targeting long non-coding RNAs as new modulators in anti-EGFR resistance mechanisms. BioImpacts : BI 14 (1) (2023)
Azam Safary, Mostafa Akbarzadeh-Khiavi, Morteza Mahmoudi, Yadollah Omidi
SARS-CoV-2 vaccine-triggered autoimmunity: Molecular mimicry and/or bystander activation of the immune system. BioImpacts : BI 13 (4) (2023)
Mostafa Akbarzadeh-Khiavi, Azam Safary, Yadollah Omidi
Targeting long non-coding RNAs as new modulators in anti-EGFR resistance mechanisms. BioImpacts : BI 14 (1) (2023)
Mostafa Akbarzadeh-Khiavi, Mitra Torabi, Amir-Hossein Olfati, Leila Rahbarnia, Azam Safary
Bio-nano scale modifications of melittin for improving therapeutic efficacy. Expert opinion on biological therapy 22 (7) (2022)
Azam Safary, Hakimeh Moghaddas Sani, Mostafa Akbarzadeh-Khiavi, Alireza Khabbazi, Mohammad A Rafi, Yadollah Omidi
Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses. Expert opinion on biological therapy 21 (9) (2021)
Mostafa Akbarzadeh-Khiavi, Azam Safary, Morteza Mahmoudi, Hamed Farzi-Khajeh, Abolfazl Barzegari, Rahimeh Mousavi, Mohammad Hossein Somi, Yadollah Omidi
PEGylated gold nanoparticles-ribonuclease induced oxidative stress and apoptosis in colorectal cancer cells. BioImpacts : BI 10 (1) (2019)
Mostafa Akbarzadeh-Khiavi, Azam Safary, Mohammad Hossein Somi
Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates. BioImpacts : BI 9 (3) (2019)
Azam Safary, Mostafa Akbarzadeh-Khiavi, Rahimeh Mousavi, Morteza Mahmoudi, Mohammad A Rafi
Enzyme replacement therapies: what is the best option? BioImpacts : BI 8 (3) (2018)

Mostafa Akbarzadeh-Khiavi.css-eqlu8i{font-size:small;padding-left:4px;} (Mostafa Akbarzadeh Khiavi)

Publication Activity (10 Years)

Top Topics

Top Venues

Mostafa Akbarzadeh-Khiavi (Mostafa Akbarzadeh Khiavi)